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Cartilage defects represent a common problem in orthopaedic practice. Predisposing factors include traumas, inﬂammatory
conditions, and biomechanics alterations. Conservative management of cartilage defects often fails, and patients with this lesions
may need surgical intervention. Several treatment strategies have been proposed, although only surgery has been proved to
be predictably eﬀective. Usually, in focal cartilage defects without a stable ﬁbrocartilaginous repair tissue formed, surgeons
try to promote a natural ﬁbrocartilaginous response by using marrow stimulating techniques, such as microfracture, abrasion
arthroplasty, and Pridie drilling, with the aim of reducing swelling and pain and improving joint function of the patients.
These procedures have demonstrated to be clinically useful and are usually considered as ﬁrst-line treatment for focal cartilage
defects. However, ﬁbrocartilage presents inferior mechanical and biochemical properties compared to normal hyaline articular
cartilage, characterized by poor organization, signiﬁcant amounts of collagen type I, and an increased susceptibility to injury,
which ultimately leads to premature osteoarthritis (OA). Therefore, the aim of future therapeutic strategies for articular cartilage
regeneration is to obtain a hyaline-like cartilage repair tissue by transplantation of tissues or cells. Further studies are required to
clarify the role of gene therapy and mesenchimal stem cells for management of cartilage lesions.
1.Introduction
Hyaline articular cartilage is a highly specialized tissue. The
function of cartilage is to protect the bones of diarthrodial
joints from friction, forces associated with load bearing and
impact [1, 2] .T h ep e c u l i a rp r o b l e mo ft h i st i s s u ei si t s
durability. Once articular cartilage is injured or degenerated,
it has very limited capacities for self-repair and regeneration.
In partial thickness lesions, in whom the defect is completely
contained within the articular cartilage, there is no involve-
ment of the vasculature. Consequently, chondroprogenitor
cellsfrommarroworbloodcannotreachthedamagedregion
to repair the lesion or contribute to the healing of the tissue.
The most considerable consequence of cartilage avascularity
is that articular chondrocytes are not able to migrate towards
the lesion and to produce reparative matrix to ﬁll the defect.
As such, the defect is not repaired and remains permanently
[1, 2].
Full thickness cartilage lesions result in the damage of the
chondral layer and subchondral bone plate. The rupture of
bloodvesselspromotestheformationofthehematomaatthe
injury site. In this condition, the repair response is promoted
and the defect is ﬁlled with ﬁbrocartilaginous tissue within
weeks [1, 2].
Usually, in focal cartilage defects without a stable ﬁbro-
cartilaginous repair tissue formed, surgeons try to promote
a natural ﬁbrocartilaginous response by using marrow stim-
ulating techniques, such as microfracture, abrasion arthro-
plasty, and Pridie drilling with the aim of reducing swelling
and pain and improving joint function of the patients. These
procedures have demonstrated to be clinically useful and are2 Stem Cells International
usually considered as ﬁrst-line treatment for focal cartilage
defects [3–5].
However, ﬁbrocartilage presents inferior mechanical and
biochemicalpropertiescomparedtonormalhyalinearticular
cartilage, characterized by poor organization, signiﬁcant
amounts of collagen type I, and an increased susceptibility
to injury, which ultimately leads to premature osteoarthritis
(OA).
Therefore, as outlined in the modern literature on the
subject, the aim of future therapeutic strategies for articular
cartilage regeneration is to obtain a hyaline-like cartilage
repair tissue by transplantation of tissues or cells [2, 3, 6–8].
Tissue transplantation procedures such as periosteum,
perichondrium, or osteochondral grafts have shown positive
results for a limited number of patients, especially in the
short term, but long-term clinical results are uncertain, with
tissue availability for transplant that seems to be the major
limitation,especiallyinlargecartilagedefects[2,3,6–8].The
autologous chondrocyte transplantation (ACT) procedure
has been performed since 1987 in combination with a
periosteal cover to treat chondral or osteochondral lesions of
the knee, reporting good clinical results [9–11].
Recently, several authors improved this procedure
embedding chondrocytes in a three-dimensional matrix
before transplantation into cartilage defects [4, 12, 13].
Goodresultshavealsobeenobtainedespeciallyregarding
clinical symptoms, such as pain relief and joint motion,
but none of the current treatment options has proved the
capacity to reproduce the biochemical properties of articular
hyaline cartilage [3, 10, 14].
Moreover,inthelastyears,tissueengineeringapproaches
have been investigated with the aim to produce cartilage
graftsinvitrotofacilitateregenerationofarticularcartilagein
vivo. While promising in vitro data have been obtained com-
pared to current cartilage repair options, various problems
remain unresolved for a successful repair associated with the
formation of hyaline cartilage in vivo [2, 7, 15, 16].
2. Gene Therapy
Thegenetransfertoarticulartissueswasﬁrstlydescribedand
performed by Evans et al., as a method to treat patient with
rheumatoid arthritis [17, 18]. Initial successful experiments
in several animal models using retroviral-mediated gene
delivery promoted subsequent clinical trials to evaluate the
safety and feasibility of using gene therapy for rheumatoid
arthritis [17, 18]. The study was performed on 9 patients
withoutanycomplications;allthenineparticipantstolerated
the treatment and, in addition, in all the treated joints, intra-
articular gene transfer and expression was observed [17, 18].
The relative success of these studies suggests that this new
treatment option can be used in major articular disorders
forwhichonlyunsatisfactorytreatmentoptionsarecurrently
available.
Nowadays research and recent results indicate that the
design of a successful genetic treatment for cartilage repair
and restoration includes a reﬁned strategy of gene delivery
that takes into account the complexities of treating this
particular tissue.
For the purpose of cartilage repair, potentially useful
complementary DNAs (cDNAs) include members of the
transforminggrowthfactor-(TGF-)β superfamily,including
TGF-βs1 ,2 ,a n d3 ,an u m b e ro fb o n em o r p h o g e n e t i cp r o -
teins (BMPs), insulin-like growth factor- (IGF-) 1, ﬁbroblast
growth factors (FGFs), and epidermal growth factor (EGF).
Alternatively, to support production and maintenance of
the proper hyaline cartilage matrix, delivery, and expression
of cDNAs encoding speciﬁc extracellular matrix (ECM)
components such as collagen type II, tenascin, or cartilage
oligomeric matrix protein (COMP) may also be used [19].
Another class of biologics that may be useful in cartilage
repair is represented by transcription factors that promote
chondrogenesis or the maintenance of the chondrocyte phe-
notype. SOX9 and related transcription factors (i.e., LSOX5)
and SOX6 have been identiﬁed as essential for chondrocyte
diﬀerentiation and cartilage formation [20].
Signal transduction molecules, such as SMADs, are also
known to be important regulators of chondrogenesis [21].
However, since these molecules function completely in the
intracellular environment, gene transfer may represent the
only way to harness these factors for repair, as they cannot
be delivered in soluble form.
Other secreted proteins, such as indian hedgehog (IHH)
or sonic hedgehog (SHH), play key roles in regulating
chondrocyte hypertrophy [22]a n dc o u l db eb e n e ﬁ c i a lf o r
modulating the chondrocytic phenotype of grafted cells.
Prevention or treatment of cartilage loss may also require
the inhibition of the activity of certain proinﬂammatory
cytokines, such as interleukin- (IL-) 1 and tumor necrosis
factor- (TNF-) α, as these are important mediators of
cartilage matrix degradation and apoptosis after trauma and
disease. Therefore, anti-inﬂammatory or immunmodulatory
mediators, such as interleukin-1 receptor antagonist (IL-
1Ra), soluble receptors for TNF (sTNFR) or IL-1 (sIL-1R),
IL-4 or IL-10, inhibitors of matrix metalloproteinases, and
others, may be administered to eﬀectively reduce loss of
repair cells and matrix [23].
Inhibitors of apoptosis or senescence, such as Bcl-2, Bcl-
X L ,h T E R T ,i ( N O S )a n do t h e r s ,m a ya l s ob eb e n e ﬁ c i a l l y
employed to maintain cell populations which are capable
of favourable repair responses at the injury site [24, 25].
Diﬀerent candidate cDNAs may also be administered in
combination, especially when favouring complementary
therapeutic responses. For example, the combined adminis-
tration of an anabolic growth factor (e.g., IGF-1) together
with an inhibitor of the catabolic action of inﬂammatory
cytokines (i.e., IL-1Ra) has the potential both to control the
matrix degradation and to allow partial restoration of the
damaged cartilage matrix [26, 27].
There are two general modes of intra-articular gene
delivery,adirectinvivoandanindirectexvivoapproach.The
direct in vivo approach involves the application of the vector
directly into the joint space, whereas the ex vivo approach
involves the genetic modiﬁcation of cells outside the body,
followed by retransplantation of the modiﬁed cells into the
body.
The choice of which gene transfer method as to be used
depends on several considerations, including the gene toStem Cells International 3
be delivered, and the vector used. In general, in vivo and
ex vivo delivery can be performed using adenovirus, herpes
simplex virus, adenoassociated virus vectors, lentivirus, and
nonviral vectors. Due to their inability to infect nondividing
cells, retroviral vectors are more appropriate for ex vivo
use. While ex vivo transfer methods are generally more
invasive, expensive, and technically wearisome, they ﬁnally
allow control of the transduced cells and safety testing prior
to transplantation. In vivo approaches are simpler, cheaper,
and less invasive, but these methods require the introduction
of viruses directly into the body, which limits safety testing
[28].
Towardsthetreatmentofdamagedarticularcartilage,the
three primary candidate cell types to target genetic modiﬁca-
tion are synovial lining cells, chondrocytes, and mesenchy-
mal stem cells.
Direct intra-articular injection of a recombinant vector
[29–31]representsthemoststraightforwardstrategyforgene
delivery to diseased joints. Cartilage and synovium are the
two primary tissues to be considered for this application.
Within articular cartilage, chondrocytes are present at
a low density and are located at varying depths within the
densematrix.Duetothissituation,ithasnotbeenpossibleto
achieve an eﬃcient genetic modiﬁcation of chondrocytes in
situ [32–35]. Conversely, gene delivery within the synovium
tissue has resulted much more feasible since it is usually
characterized by a thin lining of cells that covers all internal
surfaces of the joint except that of cartilage. Also, because of
its relatively large surface area, the synovium represents the
predominant site of vector interaction. Both the implant of
modiﬁed cells and direct intra-articular injection of vector
promote the synthesis and release of therapeutic proteins
into the joint space, which then bathe all available tissues,
including cartilage.
Substantial progress has been made in deﬁning the pa-
rameters that are critical for eﬀective gene transfer to syn-
ovium and prolonged intra-articular expression by using
diﬀerent types of vectors in ex vivo and in vivo approaches.
Through research conducted in the ﬁeld of rheumatoid
arthritis, the eﬀectiveness of synovial gene transfer of various
transgenes has been well documented [23]. Ex vivo gene
delivery to joints has been taken into phase I clinical trial and
shown to be feasible and safe in humans with rheumatoid
arthritis [17, 36]. Data relevant to direct intra-articular gene
delivery are beginning to emerge, although to date most of
the work in this ﬁeld has been focused towards the study
and treatment of rheumatoid arthritis, mainly because of the
potential of this approach in treating OA [37], and also to
expand repair methods of focal cartilage defects [28, 38–40].
For example, encouraging results have been reported for
adenovirally delivered IGF-1 or IL-1Ra using animal models
for OA and localized cartilage injury [32, 41].
Through both direct and ex vivo gene transfer to
synovium, it is possible to obtain biologically considerable
levels of transgene expression while for delivery of certain
growth factors, this approach is not compatible. In fact, it
was observed that adenoviral mediated delivery of TGF-β1
or BMP-2 to the synovial lining determined osteophytes,
cartilage degeneration, joint ﬁbrosis, and signiﬁcant swelling
[42–45]. In the perspective of cartilage repair, these results
suggest that synovial gene transfer may be more appropriate
for the delivery of chondroprotective agents rather than
strong anabolic transgenes with pleiotropic eﬀects of their
products. It has been shown that this property is common
to many anti-inﬂammatory cytokines.
For the gene-based delivery of certain intracellular pro-
teins or growth factors, it appears that a strategy based
on increased localization of the transgenes with the gene
products contained in the lesion of the cartilage may be
morepractical.Toachievethisgoal,themostdirectapproach
may be represented by implantation into a defect of a three-
dimensional matrix preloaded with a gene delivery vehicle,
allowinginﬁltratingcellstoacquirethevectorandsecretethe
stimulating transgene products locally [37, 46].
In order to increase the healing of ligaments and bones,
cartilage implants, activated genetically, have been designed
[47–52]. For example, it has been seen that hydrated
collagen-glycosaminoglycan matrices containing adenoviral
vectors stimulate localized reporter gene expression in vivo
for at least 21 days, after implantation into osteochondral
defects localized in rabbit knees [50].
However, it is not known yet if this type of approach can
promote an adequate biological response for repair due to
the limited cell supply commonly present at the site of the
cartilage lesion. To increase the graft cellularity, while pre-
serving the feasibility of the procedure within one operative
setting, autologous cells which are intraoperatively readily
available, such as cells from bone marrow aspirates, could
be mixed together with the genetically activated matrix. This
genetically enhanced approach for tissue engineering would
allow both the reduction of costs and execution time, while
avoiding a signiﬁcant eﬀort for the ex vivo culture of cells
[49, 50]. Nevertheless, the lack of control over gene transfer
following implantation represents a limitation for their
use.
Through the use of genetically modiﬁed chondrocytes,
attempts have been made to further improve the quality
of repaired tissue. Although chondrocytes have shown a
certain resistance to transfection with plasmid DNA, it
has been observed that some lipid-based formulations
increase the eﬃciency of DNA uptake [53]. However,
viral-based vectors are capable of producing far higher
levels of transgene expression with enhanced persistence.
It was found that transfection of monolayer-expanded
chondrocytes with viral vectors such as Moloney Murine
Leukemia Virus (MLV), lentivirus, adenovirus, and AAV
occurs promptly. It has also been shown that adenoviral-
mediated delivery of various transgenes, such as TGF-β1,
BMP-2, IGF-1, or BMP-7, stimulates the production of a
cartilage-speciﬁc matrix rich in proteoglycans and collagen
type II and reduces tendency towards dediﬀerentiation
[54–58].
It has been seen that following transfer of cDNA encod-
ing matrix molecules, such as the collagen type II minigene,
an increased extracellular matrix production occurs in
human fetal chondrocytes [37].
Collagen type II expression of chondrocytes in three-
dimensional culture in vitro has shown to be increased4 Stem Cells International
following transduction with the transcription factor SOX-
9[ 59, 60], whereas overexpression of the transcription
factor Runx-2 (Cbfa-1) promotes chondrocyte maturation
and determines a hypertrophic phenotype, expressing high
levels of collagen types II and X, alkaline phosphatase, and
osteogenic marker genes [61, 62].
Since it has been found that chondrocyte biology can be
positively inﬂuenced by genetic modiﬁcation, attention of
research has focused on their eﬃcient delivery to cartilage
defects. The delivery of genetically modiﬁed chondrocytes
in suspension has represented the ﬁrst approach. Several
studies demonstrated that after engraftment onto cartilage
explants in vitro, genetically modiﬁed chondrocytes have the
ability of expressing transgene products at functional levels
[63].
Compared to transplanted control cells, in these systems,
genetic modiﬁcation with IGF-1 [64], FGF-2 [65], or SOX9
[66] resulted in a considerable resurfacing and thicker tissue
containing increased levels of proteoglycans and collagen
type II [53]. Moreover, adenoviral-mediated IL-1Ra gene
transfer to chondrocytes led to resistance to IL-1-induced
proteoglycan degradation after engraftment [67].
Genetically modiﬁed chondrocytes have also been used
as an alternative to delivery in suspension with the aim
of enhancing tissue engineering procedures. This approach
requires the transduction/transfection in monolayer cells
subsequentlyseededintoamatrixforfurthertransplantation
into chondral or osteochondral lesions. Several transgenes
includingTGFβ1,BMP-2,-4,-7,IGF-1,SOX9,amongothers
have shown promising results in these three-dimensional
culture systems due to their ability to maintain and stimulate
the chondrogenic phenotype in vitro [16, 28, 40].
Initial studies highlighted that following genetic modiﬁ-
cations with adenoviral, AAV, retroviral, or plasmid vectors,
chondrocytes had the ability to eﬃciently express reporter
genes in chondral and osteochondral lesions, and that when
the genetically modiﬁed chondrocytes were seeded in three-
dimensional matrices, transgene expression was extended
over several weeks [68–71].
The results of eﬃcacy studies demonstrating the eﬀects
of genetically modiﬁed chondrocytes in cartilage defects in
vivo have just started to be reported.
In an ex vivo approach, adenovirally transduced chon-
drocytes expressing BMP-7 [54], integrated in a matrix of
autogenous ﬁbrin, were implanted into full thickness artic-
ular cartilage lesions in horses [54]. An enhanced tissue
volume with increased production of a proteoglycan and
collagen type II rich matrix was detected 4 weeks after
surgery in the BMP-7-treated lesions, compared to control
lesions treated with unrelated marker genes.
After 8 months, the mechanical features of the treated
lesions as well as the levels of collagen type II and proteo-
glycan were however similar compared to the controls. This
ﬁnding was attributed to some extent to the reduction of
the number of allografted chondrocytes that persisted after
8 months in the lesions [54]. Nevertheless, these ﬁndings
remain encouraging since they suggest that genetically
modiﬁed chondrocytes can be used to increase a cartilage
repair process in a large animal model.
3.Mesenchymal StemCells
Until recently, scientists have mainly focused on research
involving two types of stem cells from humans and animals:
nonembryonic “somatic” or “adult” stem cells and embry-
onic stem cells.
Embryonic stem cells are present in the blastocyst while
adult stem cells are found in adult tissues. The normal
turnover of organs that have a high intrinsic regenerative
abilitywhichincludeblood,skin,andintestinalepitheliumis
maintained by adult stem cells. Adult stem cells are generally
unipotent or multipotent and they can be found in adults as
well as adolescents and children.
Adult pluripotent stem cells are normally found in
small numbers since they are very rare. However, they are
present in several tissues including umbilical cord blood.
The adult stem cells studied most extensively to date are
the multipotent stem cells which are commonly referred
to by their tissue origin (i.e., hematopoietic stem cells that
diﬀerentiate into platelets erythrocytes, white blood cells,
etc.) and the bone marrow stromal cells (also known as
MSCs) [72, 73], which have the capacity to diﬀerentiate into
connective tissue cells.
MSCs have the potential to diﬀerentiate into cells of
connective tissue lineages [74] including bone [75–77],
cartilage [77–79], ligament [80–82], muscle [78], fat [78,
83], and IVD [81, 82, 84]. It has been detected that these
c e l l sa r ea l s oc a p a b l eo fd i ﬀerentiation along myogenic
and neurogenic lineages, although these are not the com-
mon pathways used to prove multipotentiality of isolated
MSCs.
Originally, adult MSCs were isolated from bone marrow
by Pittenger et al. in 1999 [74], who demonstrated the
potential for multilineage diﬀerentiation of these cells.
Subsequently, a number of studies allowed to demonstrate
the presence of stem cells in various adult tissues, includ-
ing synovial ﬂuid, articular cartilage, synovial membrane,
periosteum, dermis, muscle, and adipose tissue.
To date, research has allowed for MSC-like progenitor
cells isolation from trabecular bone, periosteum, synovium,
skeletal muscle, adipose tissue, deciduous teeth [78, 80], and
bone marrow [85].
SincenodeﬁnitivemarkersofMSCsareavailable,arange
of cell surface markers are normally used. These include
immunopositivity for STRO-1, CD73, CD105, CD106,
CD145, and CD166, associated with negative immunoreac-
tivity for CD11b, CD31, CD34, CD45, and CD117.
Compared to the previous methods based on either
density-gradient centrifugation or even simple plastic adher-
ence, these markers allow to identify a more homogeneous
population of cells.
Due to general heterogeneity of bone marrow cell
populations,variableresultscanbeobtained;however,MSCs
have commonly shown the ability to diﬀerentiate along
the adipogenic, chondrogenic, and osteogenic pathways.
Research conducted by several authors suggests that MSCs
are capable of diﬀerentiation to chondrocytes, osteoblasts,
and nucleus pulposus (NP) cells of the IVD [84, 86–88].
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a number of chondrocyte markers, with which they share a
large phenotypic similarity, are typically used.
AfterPittengeretal.[74]demonstratedthechondrogenic
potential of MSCs, a number of approaches promoting MSC
chondrogenesis [60]s u c ha sa g a r o s e[ 89] and alginate [90]
gels have been described and more recently a range of tis-
sue engineering biomaterials which allow or promote chon-
drogenesis have also been reported.
One of the most commonly used growth factors is TGF-
b[ 74, 91], which has shown to promote chondrogenesis in
addition to inhibiting adipogenic and osteogenic diﬀerentia-
tion [92, 93].
Growth factors of the BMP family, principally BMP-7,
and IGF-1 have also demonstrated the ability to promote
chondrogenesis of MSCs and it has also been suggested that
expansion of monolayer MSCs in medium containing FGF-
2 induces chondrogenesis following transfer to a 3D culture
environment [94–97].
However,withtheinvitrodiﬀerentiation approaches,the
complexity of the signaling pathways involved in chondroge-
nesis represents one of the major problems, compared to the
simplicity of culture systems.
Severalstudieshavedemonstratedtheimportanceofcell-
cell contact for MSC diﬀerentiation to either NP cells or
chondrocytes [73] and pellet cultures mimic the mesenchy-
mal compression that occurs during embryogenesis.
Similarly it is known that diﬀerentiation and matrix
formation are induced by anabolic growth factors that exert
their activity through a number of pathways, primarily the
Smad and MAPKinase pathways [92, 96, 98].
The routine assessment of successful chondrogenesis is
performed by the induction of SOX-9, which subsequently
promotes the production of type II collagen as well as the
enhanced expression of the PG aggrecan [99, 100]. Based
on the similarities in the phenotype of NP cells of the IVD
andarticularchondrocytes[101],thesemarkersarealsoused
routinely to identify NP-like cells since no validated and
highly speciﬁc NP marker genes are available. However, in
standard in vitro culture systems MSC diﬀerentiation has
shown to be unstable and it commonly leads to the expres-
sion of hypertrophic markers such as alkaline phosphatase
and type X collagen [91, 102].
In terms of clinical application, the likelihood that chon-
drogenic diﬀerentiation may cause hypertrophy represents a
problem since healthy surface and mid zone chondrocytes
and NP cells do not express alkaline phosphatase nor type
Xc o l l a g e n[ 103, 104].
This was demonstrated by Pelttari et al. [105] in pellet
cultures comparing MSCs and chondrocytes, who reported
that following implantation into SCID mice, the MSCs
showed high levels of alkaline phosphatase and type X
collagen expression which induced vascular invasion and
calciﬁcation, while chondrocytes produced a cartilaginous
matrix.
Improveddiﬀerentiationorterminaldiﬀerentiationinhi-
bition may be induced with a number of growth factors. For
example, it has been observed that the addition of PTHrP
to TGF-b3-stimulated MSCs in poly-glycolic acid scaﬀolds
also inhibits the expression of type X collagen of these cells
and suppresses their terminal diﬀerentiation [106]. Also, the
combination of TGF-b3 with BMP-2 has shown improved
chondrogenic diﬀerentiation of MSCs compared to either
growth factor alone or the combination of TGF-b3 with
either BMP-4 or BMP-6 [107].
4. Conclusions
Hyaline articular cartilage is a highly specialized tissue. The
peculiar problem of this tissue is that once articular cartilage
is injured or degenerated, it has very limited capacities for
self-repair and regeneration.
Usually, in focal cartilage defects without a stable ﬁbro-
cartilaginous repair tissue formed, surgeons try to promote
a natural ﬁbrocartilaginous response by using marrow
stimulating techniques, such as microfracture, abrasion
arthroplasty, and Pridie drilling [108–111].
However, ﬁbrocartilage presents inferior mechanical and
biochemicalpropertiescomparedtonormalhyalinearticular
cartilage, characterized by poor organization, signiﬁcant
amounts of collagen type I, and an increased susceptibility to
injury, which ultimately leads to premature OA [112–114].
The implementation of gene transfer techniques may
allow to overcome the limitations of the current treatments
for articular cartilage lesions. It has been shown that various
approaches could be appropriate for an eﬃcient transfer
of exogenous cDNAs to cartilage lesions in vivo and for
achieving sustained expression of the related gene products.
Initial eﬃcacy studies have proven that gene-transfer
techniques represent potent tools able to promote a sig-
niﬁcant biological response in vivo. However, the safety
of gene transfer approaches for cartilage repair is also of
particular importance because cartilage injuries are not life-
threatening. Therefore the application of this technology for
clinical use is strongly dependent on the use of safe and
eﬃcient delivery systems vectors and transgenes.
Although a number of animal models for OA and other
types of arthritis are available, none of them allow to predict
the equivalent disease in humans and most them are linked
with problems. Further studies are required to establish the
role of stem cells and gene therapy for cartilage repair.
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